PROfound: Phase III study of the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair gene mutations (HRRm)

Affiliation auteurs!!!! Error affiliation !!!!
TitrePROfound: Phase III study of the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair gene mutations (HRRm)
Type de publicationJournal Article
Year of Publication2019
AuteursSandhu S, Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Chi K, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman C, de Bono J
JournalASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
Volume15
Pagination122
Date PublishedNOV
Type of ArticleMeeting Abstract
ISSN1743-7555